Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic-ecollection
Document type Published Erratum
PubMed
38495081
PubMed Central
PMC10941979
DOI
10.3389/fonc.2023.1343027
Knihovny.cz E-resources
- Keywords
- bone metastases, lenvatinib, liver metastases, lung metastases, pembrolizumab, renal cell carcinoma, sarcomatoid histology, sunitinib,
- Publication type
- Published Erratum MeSH
[This corrects the article DOI: 10.3389/fonc.2023.1223282.].
Biostatistics Eisai Inc Nutley NJ United States
Clinic for Medical Oncology and Clinic for Urology University Hospital Essen Essen Germany
Clinical Research Eisai Inc Nutley NJ United States
Clinical Research Eisai Ltd Hatfield United Kingdom
Clinical Research Merck and Co Inc Rahway NJ United States
Department of Biomedical Sciences and Human Oncology University of Bari 'A Moro' Bari Italy
Department of Medical Oncology Dana Farber Cancer Institute Boston MA United States
Department of Medical Oncology Hospital de la Santa Creu i Sant Pau Barcelona Spain
Department of Medicine Memorial Sloan Kettering Cancer Center New York NY United States
Department of Oncology Charles University and Thomayer University Hospital Prague Czechia
Department of Oncology University of Western Ontario London ON Canada
Department of Urology Kyushu University Fukuoka Japan
Department of Urology Tokyo Women's Medical University Tokyo Japan
Global Clinical Development Merck and Co Inc Rahway NJ United States
ICON Research South Brisbane and University of Queensland St Lucia QLD Australia
Medical Oncology Texas Oncology Dallas TX United States
State Institution of Healthcare Regional Clinical Oncology Dispensary Omsk Russia
References provided by Crossref.org
